

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(d))

Docket No.
RLL-192CIPUS

In Re Application Of: **MEHTA et al.**

JAN 18 2005

Application	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/051,784	1/17/2002	McKenzie, Thomas C.	26,815	1624	2737

Title: **OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS**

Address to:
Commissioner for Patents

The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(c), and on or before payment of the issue fee, and is accompanied by the Statement as specified in 37 CFR 1.97(e) and the fee set forth in 37 CFR 1.17(p).

- ☐ A check in the amount of _____ is attached.
- ☒ Charge Deposit Account No. **50-0912** in the amount of **\$180.00**
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office	
(Fax no. _____)) on _____
(Date)	
_____ Signature	
_____ Typed or Printed Name of Person Signing Certificate	

*This certificate may only be used if paying by deposit account.

George E. Heibel
Signature


George E. Heibel, Esq.
Reg. No. 42,648
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Telephone: (609) 720-5334
Facsimile: (609) 514-9779

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on	
January 12, 2005	
(Date)	
_____ Signature of Person Mailing Correspondence	
Christine Kenedy	
_____ Typed or Printed Name of Person Mailing Certificate	

Dated: **January 12, 2005**

CC:



STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

Docket No.
RLL-192CIPUS

Application Of: MEHTA et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/051,784	1/17/2002	McKenzie, Thomas C.	26,815	1624	2737

Invention: OXAZOLIDINONE DERIVATIVES AS POTENTIAL ANTIMICROBIALS

COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☐ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☒ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

George E. Heibel, Esq.
Reg. No. 42,648
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Telephone: (609) 720-5622
Facsimile: (609) 514-9779

Dated: January 12, 2005

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 12, 2005

(Date)

Signature of Person Mailing Correspondence

Christine Kenedy

Typed or Printed Name of Person Mailing Correspondence

CC:

SUPPLEMENTAL

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket No.
RLL-192CIPUS

Serial No. 10/051,784

Applicants: MEHTA *et al.*

Filed: 1/17/2002

Group: 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
1						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SC1	Blake and Metcalfe, "A Shared Noncapsular Antigen Is Responsible for False-Positive Reactions by <i>Staphylococcus epidermis</i> in Commercial Agglutination Tests for <i>Staphylococcus aureus</i> ", <i>Journal of Clinical Microbiology</i> , 39(2):544-550 (2001)
SC2	BORCH <i>et al.</i> , "Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkalyting Agents," <i>Journal of Medicinal Chemistry</i> , 43:2258-2265 (2000)
SC3	Fournari and Tirouflet, <i>Bull. Soc. Chim. France</i> , p 484-487 (1963)
SC4	<i>Chemical Abstracts</i> , 71:332, abst. 101697d (1969)
SC5	Mermel <i>et al.</i> , "Guidelines for the Management of Intravascular Catheter-Related Infections", <i>Clinical Infectious Diseases</i> , 32:1249-1272 (2001)
SC6	DIVALD, <i>et al.</i> , "Chemistry of 2-(Chloromethyl)furans. Reaction of 2-(Chloromethyl)futans with Aqueous Potassium Cyanide and Other Nucleophiles", <i>Journal of Organic Chemistry</i> , 41:2835-2845 (1976)
SC7	GILMAN <i>et al.</i> , "Orientation in the Furan Nucleau:, VI. β - Substituted Furans", <i>Journal of the American Chem. Society</i> , 55:2903-2909 (1933)
SC8	HULBERT, <i>et al.</i> , "Structure and Antischistosomal Activity in the Nitrofuran Series. Requirement for a 5-Nitro-2-furyl Vinyl Moiety Based on Comparison of 3-5-Nitro-2-furyl-Substituted Propionic, Acrylic, and Propiolic Acid Derivatives.", <i>Journal of Medicinal Chemistry</i> , 16:72-78 (1973)
SC9	Zimmerli, "Experimental models in the investigation of device-related infections", <i>Journal of Antimicrobial Chemotherapy</i> 31(Suppl. D):97-102 (1993)
SC10	<i>Khim. Geterosikl. Soedin.</i> , 6:747-50 (1982)
SC11	MAKOSZA, <i>et al.</i> , "Dihalomethylation of Nitroarenes via Vicarious Nucleophilic Substitution of Hydrogen with Trihalomethyl Carbanions.", <i>Journal of Organic Chemistry</i> , 54:5094-5100 (1989)
SC12	PARK <i>et al.</i> , "Antibacterials. Synthesis and Structure-Actitivity Studies of 3-Aryl-2-oxooxazolidines. 4. Multiply-Substituted Aryl Dervatives", <i>Journal of Medicinal Chemistry</i> , 35:1156-1165 (1992)
SC13	POLONIO <i>et al.</i> , "Eradication of Biofilm-Forming <i>Staphylococcus epidermis</i> (RP62A) by a Combination of Sodium Salicylate and Vancomycin", <i>Antimicrobial Agents and Chemotherapy</i> , 45(11):3262-3266 (2001)
SC14	TANAKA, <i>et al.</i> , "Studies on Furan Derivatives. IX. ¹⁾ Nucleophilic Substitution of 5-Nitro-2-furancarbaldehyde: Preparation of 5-Phenoxy-2-furancarbaldehydes.", <i>Chemical & Pharmaceutical Bulletin</i> , 28(9):2846-2849 (1980)
SC15	"Catheter-Related Bloodstream Infections - Developing Antimicrobial Drugs for Treatment", <i>FDA Guidance for Industry</i> (October 1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.